Literature DB >> 35377729

Is Dose-Adjusted EPOCH-R Less Effective in Children Than Adults With Primary Mediastinal B-Cell Lymphoma?

Rahul Lakhotia1, Christopher Melani1, Mark Roschewski1, Wyndham H Wilson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35377729      PMCID： PMC9197344          DOI： 10.1200/JCO.21.02593

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   50.717


× No keyword cloud information.
  10 in total

1.  Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.

Authors:  M Gutierrez; B A Chabner; D Pearson; S M Steinberg; E S Jaffe; B D Cheson; A Fojo; W H Wilson
Journal:  J Clin Oncol       Date:  2000-11-01       Impact factor: 44.544

2.  Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Authors:  Nancy L Bartlett; Wyndham H Wilson; Sin-Ho Jung; Eric D Hsi; Matthew J Maurer; Levi D Pederson; Mei-Yin C Polley; Brandelyn N Pitcher; Bruce D Cheson; Brad S Kahl; Jonathan W Friedberg; Louis M Staudt; Nina D Wagner-Johnston; Kristie A Blum; Jeremy S Abramson; Nishitha M Reddy; Jane N Winter; Julie E Chang; Ajay K Gopal; Amy Chadburn; Susan Mathew; Richard I Fisher; Kristy L Richards; Heiko Schöder; Andrew D Zelenetz; John P Leonard
Journal:  J Clin Oncol       Date:  2019-04-02       Impact factor: 44.544

3.  The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.

Authors:  R M Meyer; W M Hryniuk; M D Goodyear
Journal:  J Clin Oncol       Date:  1991-02       Impact factor: 44.544

4.  A prospective study of mediastinal gray-zone lymphoma.

Authors:  Wyndham H Wilson; Stefania Pittaluga; Alina Nicolae; Kevin Camphausen; Margaret Shovlin; Seth M Steinberg; Mark Roschewski; Louis M Staudt; Elaine S Jaffe; Kieron Dunleavy
Journal:  Blood       Date:  2014-07-14       Impact factor: 22.113

Review 5.  Insights into Doxorubicin-induced Cardiotoxicity: Molecular Mechanisms, Preventive Strategies, and Early Monitoring.

Authors:  Nadine Wenningmann; Merle Knapp; Anusha Ande; Tanaya R Vaidya; Sihem Ait-Oudhia
Journal:  Mol Pharmacol       Date:  2019-06-04       Impact factor: 4.436

Review 6.  CNS involvement in primary mediastinal large B-cell lymphoma.

Authors:  P C Bishop; W H Wilson; D Pearson; J Janik; E S Jaffe; P C Elwood
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

7.  Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study.

Authors:  Mary Gerrard; Mitchell S Cairo; Claire Weston; Anne Auperin; Ross Pinkerton; Anne Lambilliote; Richard Sposto; Keith McCarthy; Marie-José T Lacombe; Sherrie L Perkins; Catherine Patte
Journal:  Br J Haematol       Date:  2008-03-26       Impact factor: 6.998

8.  Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.

Authors:  Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson
Journal:  N Engl J Med       Date:  2013-04-11       Impact factor: 91.245

9.  Dose-Adjusted Etoposide, Doxorubicin, and Cyclophosphamide With Vincristine and Prednisone Plus Rituximab Therapy in Children and Adolescents With Primary Mediastinal B-Cell Lymphoma: A Multicenter Phase II Trial.

Authors:  G A Amos Burke; Veronique Minard-Colin; Anne Aupérin; Sarah Alexander; Marta Pillon; Rafael Delgado; József Zsíros; Anne Uyttebroeck; Peggy Dartigues; Rodney R Miles; Bernarda Kazanowska; Alan K Chiang; Stéphanie Haouy; Catherine M Bollard; Monika Csoka; Keith Wheatley; Donald A Barkauskas; Peter C Adamson; Gilles Vassal; Catherine Patte; Thomas G Gross
Journal:  J Clin Oncol       Date:  2021-09-27       Impact factor: 50.717

10.  Dose-adjusted EPOCH-rituximab or intensified B-NHL therapy for pediatric primary mediastinal large B-cell lymphoma.

Authors:  Fabian Knörr; Martin Zimmermann; Andishe Attarbaschi; Edita Kabíčková; Britta Maecker-Kolhoff; Stephanie Ruf; Ingrid Kühnle; Martin Ebinger; Anne-Kathrin Garthe; Ingrid Simonitsch-Klupp; Ilske Oschlies; Wolfram Klapper; Birgit Burkhardt; Wilhelm Woessmann
Journal:  Haematologica       Date:  2021-12-01       Impact factor: 9.941
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.